'As good as it gets': Fauci hails Moderna's COVID-19 vaccine result as 'truly outstanding'

After Moderna Inc anunced that its COVID-19 vaccine is 94.5% effective against vel coronavirus based on preliminary data, US top infectious disease expert Dr Anthony Fauci called it “exciting results”. While Moderna heard its results on a call on vember 16 along with members of Data Safety and Monitoring Board which is an independent panel analyzing company’s clinical trial data, as per CNN report, Fauci said that “It's just as good as it gets -- 94.5% is truly outstanding.”

Moderna Inc, American pharmaceutical company has informed that it plans on submitting its COVID-19 vaccine candidate for an Emergency Use Authorization (EUA) with United States' Food & Drug ministration (FDA). analysis released by Moderna which has reported 94.5% efficacy of COVID-19 vaccine was based on results of more than 30,000 participants in US. 

Hailing progress in vaccine development, US top infectious disease expert and member of coronavirus task force said that vaccinations could begin in second half of December. As per reports, especially in United States, vaccinations are expected to start off with high-risk or vulnerable groups and for rest of population, it will be available by 2021 spring. Moderna’s chief medical officer, Dr Tal Zacks, also welcomed achievements as “one of greatest moments” of his life. He reportedly said, “It is absolutely amazing to be able to develop this vaccine and see ability to prevent symptomatic disease with such high efficacy.”

Re - Coronavirus LIVE Updates: India's Tally At 88,74,291; Moderna Says Vaccine 94.5% Effective

Re - Bach: Athletes Taking Vaccine t Just 'individual' Decision

Pfizer-BioNTech vaccine is 90% effective

t only Moderna, even American pharmaceutical company Pfizer said on vember 9 that interim analysis of its vaccine produced along with German partner BioNTech group has shown promising results, meaning it is on track to file an emergency use application with American regulators as early as later this month. Pfizer-BioNTech COVID-19 vaccine candidate has shown more than 90 per cent efficacy in preventing coronavirus and w two companies are working to distribute experimental drug. 

However, vember 9 anuncement does t imply that mRNA-based vaccine called BNT162b2, is imminent. results are based on interim analysis which considered at least 94 infections in a study that h enrolled at least 44,000 people in six nations including United States with fewer than nine of m who caught disease were also given dose.

Re - Some Asian Shares Buoyed By News On Coronavirus Vaccine

Re - WHO Hails COVID-19 Vaccine News But Says 'complacency Isn't An Option' As Cases Surge